Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group - Wikidata - wikimedia - TriplyDB

Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group

Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group

http://www.wikidata.org/entity/Q28344357

about

Metal-catalysed azidation of tertiary C-H bonds suitable for late-stage functionalization Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.Macrolides: A Canadian Infectious Disease Society position paper.

P2860

Q35029999-5EBC5CB1-AECC-45F7-A67E-6B66804FEC68 Q35166134-FABED468-344D-4A43-A6DB-71D44E7D98C1 Q36170393-C4FDC453-036B-4051-9E36-F8EE852275AF

P2860

Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group

http://www.wikidata.org/entity/Q28344357

description

2000 nî lūn-bûn

@nan

2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Clinical efficacy of intraveno ...... ravenous Clinical Trials Group

@ast

Clinical efficacy of intraveno ...... ravenous Clinical Trials Group

@en

Clinical efficacy of intraveno ...... ravenous Clinical Trials Group

@nl

type

label

Clinical efficacy of intraveno ...... ravenous Clinical Trials Group

@ast

Clinical efficacy of intraveno ...... ravenous Clinical Trials Group

@en

Clinical efficacy of intraveno ...... ravenous Clinical Trials Group

@nl

prefLabel

Clinical efficacy of intraveno ...... ravenous Clinical Trials Group

@ast

Clinical efficacy of intraveno ...... ravenous Clinical Trials Group

@en

Clinical efficacy of intraveno ...... ravenous Clinical Trials Group

@nl

P1433

Q28344357-14D03A91-66B7-44F9-8EE2-32EF894A0312

P1476

Q28344357-495F5DB5-43C4-4410-AFAE-2711A24B8882

P2093

Q28344357-018796B4-98B0-477D-8AF8-47BC3947F9DC

Q28344357-1E6E0ED0-7F66-4A9E-AA02-8F6068AB1D12

Q28344357-2C7A39CA-F9F9-40B4-890E-46FB931336F7

Q28344357-3BA6A211-BDF8-4CD0-9D1B-FA4D7270D81D

Q28344357-6CA7703E-0471-4DBA-B95D-16D8F3FB007D

Q28344357-6D2D1BF0-3344-4278-9DF6-D913DA83AF63

Q28344357-7C2E7834-6EFB-4B1E-B360-F9BC64BA07D2

Q28344357-9099F506-5722-417C-8B83-35F9AC80EC4A

Q28344357-985FB539-DAFB-4194-BAF0-4BAB501AAF1E

Q28344357-B31032AC-4FEC-45B7-A540-DE8BD9BBCFA3

P2860

Q28344357-1529B3F3-3B0B-457C-BC64-1236A923F43D

Q28344357-18F28A68-BC94-47A2-A718-1E5696A695B0

Q28344357-1D9A733E-BE07-400F-8D4A-5A11A210CB7B

Q28344357-1F6FA579-8F5C-4402-A498-78C8A1C7C292

Q28344357-3FA718D0-9C86-4664-9363-DB4C8B8B933E

Q28344357-465908D2-E8EA-48E7-BFEC-748B03A4E828

Q28344357-46CC1DBF-D853-4AD1-AD72-A759CDFF11C0

Q28344357-6C7A5929-A923-4817-862B-A51A64842E55

Q28344357-755E699C-E8CA-4C9A-9BEB-263DA946A3C8

Q28344357-894D7AF6-10A9-4B97-84EB-4BF19FEF7FA6

P304

Q28344357-ABC53420-346F-41B8-BAA0-82CC8D34A050

P31

Q28344357-1B62DF77-5538-4CC2-B9CC-3DF875AE3808

P407

Q28344357-C6A82B5B-C252-4582-9B03-C07128E56D91

P433

Q28344357-937D32F3-1116-44AF-9B4D-FCFC203E2A02

P478

Q28344357-0F28BBE9-9B5D-4F37-BE24-9E6CA4F9CD14

P577

Q28344357-ADE623F0-460D-450E-ABE9-88BFCF57F65B

P698

Q28344357-D6756821-4AC8-477C-8901-F841DE329E01

P921

Q28344357-036B0FBD-3E6E-44C0-8FDB-9839BBA7BA41

Q28344357-47787125-AF23-4B5A-9490-221BB953CB04

Q28344357-DD22B547-CCA9-47AF-B1DF-06DF180E7923

P932

Q28344357-73BFD4A5-926B-4BC1-B342-2AA676B1D489

P1433

Antimicrobial Agents and Chemotherapy

P1476

Clinical efficacy of intraveno ...... ravenous Clinical Trials Group

@en

P2093

A Anzuetto

http://www.w3.org/2001/XMLSchema#string

A Kolokathis

http://www.w3.org/2001/XMLSchema#string

B Suh

http://www.w3.org/2001/XMLSchema#string

B W Sherman

http://www.w3.org/2001/XMLSchema#string

C A Knirsch

http://www.w3.org/2001/XMLSchema#string

D B Schwartz

http://www.w3.org/2001/XMLSchema#string

J A Gezon

http://www.w3.org/2001/XMLSchema#string

J A Paladino

http://www.w3.org/2001/XMLSchema#string

J A Ramirez

http://www.w3.org/2001/XMLSchema#string

J Inverso

http://www.w3.org/2001/XMLSchema#string

P2860

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

A prediction rule to identify low-risk patients with community-acquired pneumonia

Delivery of antibiotics by phagocytes.

Tissue-directed antibiotics and intracellular parasites: complex interaction of phagocytes, pathogens, and drugs.

Intravenous azithromycin.

In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.

Community-acquired pneumonia requiring hospitalization: 5-year prospective study.

Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis.

In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens

A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.

P304

1796-802

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2000-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10858333

http://www.w3.org/2001/XMLSchema#string

P921

hospitalization

P932

89964

http://www.w3.org/2001/XMLSchema#string